15Nov 2019

MULTIPLE MYELOMA ONCOGENE - 1 (MUM - 1) DETECTION BY FLOW CYTOMETRY TECHNIQUE IN SOME B - CELL MALIGNANCIES

  • Department of Clinical Pathology, Faculty of Medicine, Al-Azhar University.
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background: Multiple Myeloma Oncogene 1 (MUM1)/ interferon regulatory factor 4 (IRF4) is a member of the interferon regulatory factor family of transcription factors. It was thought to play an important role in the pre-B cell development, receptor editing, germinal center reaction as well as plasma cell generation. This retrospective study aimed to assess MUM1/ IRF4 diagnostic value as a step for further studies to determine its significance in therapeutic strategies for B cell malignancies. Methods: A total of 60 individuals were enrolled in this study. They were divided into two groups; the patient group, which included 40 newly diagnosed B cell malignancies patients (40 to 80 years old), 24 (60%) males and 16 (40%) females. They included 20 cases of Multiple Myeloma, 10 cases of Chronic lymphocytic Leukemia and 10 cases of Non-Hodgkin Lymphoma. The control group included 20 random subjects of cases other than B cell malignancies. Patients were diagnosed by flow cytometric immunophenotyping using routine panel of monoclonal antibodies for B cell malignancies followed by MUM1/IRF4 detection using anti MUM1/IRF4 monoclonal antibodies Kit (MACS, Milteny Biotec Inc., USA). Results: MUM1/IRF4 showed highest statistical difference among multiple myeloma group than among Chronic Lymphocytic Leukemia group and least among Non-Hodgkin Lymphoma and control groups. Average expressions were 93.1%, 24.2%, 6.5% and 0.6% respectively. Conclusion: MUM1/IRF4 had a significant role as a diagnostic marker in multiple myeloma.


  1. Gualco G, Lawrence MW, Carlos EB. MuM1/IRF4 A Review. Appl Immunohistochem Mol Morphol 2010; 18: 301-10.
  2. Bollig N, Brustle A, Kellner K, Ackermann W, Abass E, Raifer H, et al. Transcription factor IRF4 determines germinal center formation through follicular T-helper cell differentiation. Proc Natl Acad Sci USA 2012; 109: 8664?9.
  3. Shukla V, Ma S, Hardy RR, Joshi SS, Lu R. A role for IRF4 in the development of CLL. Blood 2013; 122:2848?55.
  4. Nayar R. TCR signaling via Tec kinase ITK and interferon regulatory factor 4 (IRF4) regulates CD8+T-cell differentiation. Proc Natl Acad Sci USA 2012; 109: E2794-802.
  5. Biswas PS. Dual regulation of IRF4 function in T and B cells is required for the coordination of T?B cell interactions and the prevention of autoimmunity. J Exp Med 2012; 209: 581-96.
  6. Heintel D, Zojer N, Schreder M, K Strasser-Weippl K, Kainz B, Vesely M, et al. Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma. Leukemia 2008; 22: 441?5.
  7. Agnarelli A, Chevassut T, Mancini IRF4 in multiple myeloma?Biology, disease and therapeutic target. Leukemia Res 2018; 72: 52-8.
  8. Zhang S, Xu J, Wu S, Wang R, Qu X, Yu W, et al. IRF4 promotes cell proliferation by JNK pathway in multiple myeloma. Med Oncol 2016; 30(2):594.
  9. Butrym A, Lacina P, Rybka J, Chaszczewska-Markowska M, Mazur G, Bogunia-Kubik K. Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma. Arch Immunol Ther Exp (Warsz). 2017; 64(Suppl. 1):151-6.
  10. Jeong T, Chan-Jeoung Park C, Shim H, Seongsoo Jang S, Chi H, Yoon DH, et al. Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells. Korean J Hematol 2012; 47(4): 260?6.
  11. Kawano Y, Fujiwara S, Naoko Wada N, Izaki M, Yuki H, Yutaka Okuno Y, et al. Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide. Int J Oncol 2012; 41(3): 876?84.
  12. Zhang QY, Richards CD, Evans M. A retrospective study to assess the relative value of peripheral blood, bone marrow aspirate and biopsy morphology, immunohistochemical stains, and flow cytometric analysis in the diagnosis of chronic B cell lymphoproliferative neoplasms. Int J Lab Hematol 2015; 37(3):390-402.
  13. Ubieta K, Garcia M, Gr?tsch B, Uebe S, Weber GF, Stein M, et al. Fra-2 regulates B cell development by enhancing IRF4 and Foxo1 transcription. J Exp Med 2017; 214(7):2059-71.
  14. Brown JR. Inherited susceptibility to chronic lymphocytic leukemia: evidence and prospects for the future. Ther Adv Hematol 2013; 4(4):298-308.
  15. Wang L, Yao ZQ, Moorman JP, XU Y, Ning S. Gene Expression Profiling Identifies IRF4-Associated Molecular Signatures in Hematological Malignancies. PLoS One 2014; 10; 9(9): e106788.
  16. Lu TX, Yi Miao Y, Wu JZ, Gong QX, Liang JH, Wang Z, et al. The distinct clinical features and prognosis of the CD10+ MUM1+ and CD10− Bcl6− MUM1− diffuse large B-cell lymphoma. Sci Rep 2016; 6: 20465.
  17. Gualco G, Weiss LM, Harrington WJ, Bacchi CE. BCL6, MUM1 and CD10 expression in mantle cell lymphoma. Appl Immunohistochem Mol Morphol 2011; 18(2): 103?8.
  18. Oliveira CC, Maciel-Guerra H, Kucko L, Hirama EJ, Brilhante AD, Quevedo FC, et al. Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma. Diagn Pathol 2017; 12(1): 3.
  19. Uranishi M, Iida S, Sanda T, Ishida T, Tajima E, Ito M, et al. Multiple myeloma oncogene 1 (MUM1)/interferon regulatory factor 4 (IRF4) upregulates monokine induced by interferon-c (MIG) gene expression in B-cell malignancy. Leukemia 2005; 19: 1471?8.

[Karima A. Mahfoz, Ashraf A. Sayed, Ahmed M. Moharam (2019); MULTIPLE MYELOMA ONCOGENE - 1 (MUM - 1) DETECTION BY FLOW CYTOMETRY TECHNIQUE IN SOME B - CELL MALIGNANCIES Int. J. of Adv. Res. 7 (Nov). 756-763] (ISSN 2320-5407). www.journalijar.com


Ahmed M. Moharam
MD student, Department of Clinical Pathology, Faculty of Medicine, Al-Azhar University.

DOI:


Article DOI: 10.21474/IJAR01/10069      
DOI URL: https://dx.doi.org/10.21474/IJAR01/10069